Supernus Pharmaceutical (SUPN) 'Doubles' on Tentative FDA Approval

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. TGT
2. EL
3. SPY
4. WMT
5. ROST

6. BILL
7. ADI
8. MRK
9. MRNA
10. LOW

June 26, 2012 10:04 AM EDT

Price: $47.45 -2.25%

Overall Analyst Rating:
SELL (= Flat)

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) continues to rip higher following tentative FDA approval for Trokendi XR. Shares have now doubled.

Momentum Movers

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!